The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Viral inactivation is the process of rendering a virus incapable of causing infection. It plays a critical role across multiple fields, including clinical medicine, diagnostics, research, and the food industry. In clinical practice, inactivation is essential for preventing viral transmission through blood products—such as transfusions and other biological materials—as well as in biopharmaceutical manufacturing. In diagnostic and research contexts, inactivation enables the safe study and manipulation of viruses without risking transmission to laboratory staff or healthcare personnel. Moreover, in vaccine development, inactivated viruses are employed to stimulate the host immune system, promoting the production of neutralizing antibodies. A wide range of viral inactivation techniques exist, ranging from physical removal by filtration to mechanical and chemical methods. The choice of technique depends on the specific context and intended purpose. In many situations, a combination of methods is employed—particularly when handling highly pathogenic viruses—where absolute sterility is crucial. Some of the more common viruses removed by these methods are the HIV-1 and HIV-2 viruses; hepatitis A, B, and C; and parvoviruses.
Developed over the course of five years, Entropy: Zero 2 was released in August 2022 to positive reviews on Steam, and went on to win Mod DB's 2022 "Mod of the Year" award in the "Players Choice" category. Flipside - A side-scrolling platform game that allows the player to "flip" the game world around to its backside, altering the means a player can traverse a level. Half-Life 2: Overcharged - A single-player mod for Half-Life 2 that adds new enemies and locations as well as cut content, extending the base game. Originally released in 2022, the mod gained notoriety in 2024 due to the mod developers blacklisting content creators that criticized the mod by targeting their Steam IDs and crashing their game. This led to the mod being review bombed on Mod DB. Jurassic Life - A modification based on the first Jurassic Park film. The game acts as a side story to the movie where the player takes the role of the park's game warden, Robert Muldoon. Korsakovia - A single-player mod for Half-Life 2. It was developed by The Chinese Room and released September 19, 2009. In Korsakovia, the player travels through the delusions of Christopher, a man suffering from Korsakoff's Syndrome. The player hears the voices of Christopher and a doctor as they try to work out what is wrong with Christopher. Minerva - An episodic single-player mod based in the Half-Life 2 universe, using storytelling inspired by classic games such as Marathon and System Shock. Operation Black Mesa - An upcoming remake of the Half-Life expansion Opposing Force developed by Tripmine Studio.
==== Hormones and steroids ==== There is theoretical concern, and animal evidence, that environmental hormones and chemicals may affect aspects of prenatal or postnatal sexual development in humans. Bisphenol A (BPA) is a chemical used to make plastics, and is frequently used to make baby bottles, water bottles, sports equipment, medical devices, and as a coating in food and beverage cans. Scientists are concerned about BPA's behavioral effects on fetuses, infants, and children at current exposure levels because it can affect the prostate gland, mammary gland, and lead to early puberty in females. BPA mimics and interferes with the action of estrogen—an important reproduction and development regulator. It leaches out of plastic into liquids and foods, and the Centers for Disease Control and Prevention (CDC) found measurable amounts of BPA in the bodies of more than 90 percent of the U.S. population studied. The highest estimated daily intakes of BPA occur in infants and children. Many plastic baby bottles contain BPA, and BPA is more likely to leach out of plastic when its temperature is increased, as when one warms a baby bottle or warms up food in the microwave.
== Measuring principle == The ratio, the purity, and the concentration of two enantiomers can be measured via polarimetry. Enantiomers are characterized by their property to rotate the plane of linear polarized light. Therefore, those compounds are called optically active and their property is referred to as optical rotation. Light sources such as a light bulb, Tungsten Halogen, or the sun emit electromagnetic waves at the frequency of visible light. Their electric field oscillates in all possible planes relative to their direction of propagation. In contrast to that, the waves of linear-polarized light oscillate in parallel planes. If light encounters a polarizer, only the part of the light that oscillates in the defined plane of the polarizer may pass through. That plane is called the plane of polarization. The plane of polarization is turned by optically active compounds. According to the direction in which the light is rotated, the enantiomer is referred to as dextro-rotatory or levo-rotatory. The optical activity of enantiomers is additive. If different enantiomers exist together in one solution, their optical activity adds up. That is why racemates are optically inactive, as they nullify their clockwise and counter clockwise optical activities. The optical rotation is proportional to the concentration of the optically active substances in solution. Polarimeters may therefore be applied for concentration measurements of enantiomer-pure samples.
Sources: en.wikipedia.org
== Medical uses == In the US, bempedoic acid is indicated for the treatment of hypercholesterolemia in combination with diet and the highest tolerated statin therapy in adults with heterozygous familial hypercholesterolemia, or with established atherosclerotic cardiovascular disease, who need additional lowering of LDL cholesterol. In the EU, bempedoic acid is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin; or alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated. Evidence for primary prevention is limited. A secondary analysis from the largest trial showed the potential for benefit in primary prevention; however, the number of individuals was small, and all participants were at high risk for ASCVD.
Volanesorsen was approved by the European Medicines Agency (EMA) for the treatment of familial chylomicronaemia syndrome in May 2019. In January 2013 mipomersen (marketed as Kynamro) was approved by the FDA for the treatment of homozygous familial hypercholesterolemia. Inotersen received FDA approval for the treatment of hereditary transthyretin-mediated amyloidosis in October 2018. The application for inotersen was granted orphan drug designation. It was developed by Ionis Pharmaceuticals and licensed to Akcea Therapeutics. Patisiran (sold under Onpattro) was developed by Alnylam Pharmaceuticals, and also approved for use in the US and EU in 2018 with orphan drug designation. Its mechanism-of-action is the active substance of small interfering RNA (siRNA), which allows it to interfere with and block the production of transthyretin. As such, it was the first FDA-approved siRNA therapeutic.
The protein is 82.3 kDa and has a 40 amino acid long LEM domain located at its amino-terminal region. In its carboxyl end it has a RNA recognition motif (RRM). The LEM domain is also common to two other integral proteins of the INM: lamina-associated polypeptide 2 (LAP2) and emerin. The LEM segment enables LEMD3 to attach to the barrier-to-autointegration factor (BAF), and therefore, indirectly interact with the chromatin. LEMD3 also has several implications in regulating the cytokine family such as the transforming growth factor beta (TGF-β) and bone morphogenic protein (BMPs). The RRM domain in its carboxylic region attaches to the SMAD (protein) proteins, which is involved in mediating TGF-β cellular signalling. Consequently, LEMD3 indirectly regulates downstream genes. LEMD3 seems to play an important role in regulating the expression of several fundamental genes. LEMD3 has been associated with laminopathies as well as osteopoikilosis. Mutations in the LEMD3 gene have been linked to several genetic diseases such as osteopoikilosis, melorheostosis and Buschke–Ollendorff syndrome.
Sources: en.wikipedia.org
=== Stagnation and a forfeited World Cup (1976–1986) === Runners-up status brought no lasting improvement. Colombia failed to win any of their four matches in the 1978 qualifiers, managing one goal across the group and losing 6–0 in Rio de Janeiro. At the 1979 Copa América they again finished level on points with Chile after beating them 1–0 in Bogotá and putting four past Venezuela, only to be eliminated on goal difference following a 2–0 defeat in Santiago. The 1982 campaign, overseen by the Argentine Carlos Bilardo, yielded two points from four matches and no victories, Hernán Darío Herrera scoring three of Colombia's four goals. A second-place group finish behind Peru ended the 1983 Copa América campaign.
Rather than binding specific ligands, olfactory receptors display affinity for a range of odorant molecules, and conversely a single odorant molecule may bind to a number of olfactory receptors with varying affinities, which depend on physio-chemical properties of molecules like their molecular volumes. Once the odorant has bound to the odorant receptor, the receptor undergoes structural changes and it binds and activates the olfactory-type G protein on the inside of the olfactory receptor neuron. The G protein (Golf and/or Gs) in turn activates the lyase – adenylate cyclase – which converts ATP into cyclic AMP (cAMP). The cAMP opens cyclic nucleotide-gated ion channels which allow calcium and sodium ions to enter into the cell, depolarizing the olfactory receptor neuron and beginning an action potential which carries the information to the brain.
The last two gates were directly opposite the Red Square, while the Konstantino-Eleninsky gate was located behind Saint Basil's Cathedral. The Russian famine of 1601–1603 killed possibly 100,000 people in Moscow. Between 1610 and 1612, troops of the Polish–Lithuanian Commonwealth occupied Moscow, as its ruler Sigismund III tried to take the Russian throne. In 1612, Nizhny Novgorod and other Russian cities, led by prince Dmitry Pozharsky and Kuzma Minin, rose against the Polish occupants, besieged the Kremlin, and expelled them. In 1613, the Zemsky Sobor (lit. 'assembly of the land'; parliament) elected Michael Romanov as tsar, establishing the Romanov dynasty. The 17th century witnessed several uprisings—such as the liberation of Moscow from Polish–Lithuanian invaders (1612), the Salt Riot (1648), the Copper Riot (1662), and the Moscow uprising of 1682. During the first half of the 17th century, Moscow's population doubled from 100,000 to 200,000, and it expanded beyond its ramparts in the latter part of the century. In the middle of the 17th century, 20% of Moscow suburban inhabitants came from the Grand Duchy of Lithuania, having been driven from their homeland by Muscovite invaders. By 1682, 692 households were established north of the ramparts—by Ukrainians and Belarusians abducted from their hometowns during the Russo-Polish War of 1654–1667. These new outskirts became known as the Meshchanskaya sloboda (settlement), after the Ruthenian term meshchane meaning "town people".
== Further reading == Kielley WW, Bradley LB (1954). "Glutathione thiolesterase". J. Biol. Chem. 206 (1): 327–33. doi:10.1016/S0021-9258(18)71321-5. PMID 13130552. Murata, Kousaku; Sato, Nobuyuki; Rhee, Hae-ik; Watanabe, Kunihiko; Kimura, Akira (1987). "Purification and Characterization of Glutathione Thiol Esterase from Saccharomyces cerevisiae". Agricultural and Biological Chemistry. 51 (7): 1901–1907. doi:10.1080/00021369.1987.10868321. Uotila, Lasse (1979). "Glutathione thiol esterases of human red blood cells". Biochimica et Biophysica Acta (BBA) - Protein Structure. 580 (2): 277–288. doi:10.1016/0005-2795(79)90140-5. PMID 93000.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.